



Aligning Patient and Clinician Goals to Improve the Care of Ovarian Cancer

Clinical Brief #2 – IO for Platinum-Resistant OC

References

Tweet 2 References:

Andre T, Berton D, Curigliano G, et al. Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. *J Clin Oncol*. 2021;39(3_suppl):9. doi:10.1200/JCO.2021.39.3_suppl.9

Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. *Ann Oncol*. 2022;33(9):929-938. doi:10.1016/j.annonc.2022.05.519

Maio M, Ascierto PA, Motola Kuba D, et al. 113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial. *Ann Oncol*. 2022;33:S589-S590. doi:10.1016/j.annonc.2022.07.145

Additional References:

Ghisoni E, Wicky A, Bouchaab H, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. *Eur J Cancer*. 2021;149:153-164. doi:10.1016/j.ejca.2021.03.010

Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. *J Immunother Cancer*. 2020;8(2):e001754. doi:10.1136/jitc-2020-001754

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (v2.2023). Updated June 2, 2023. Accessed June 22, 2023. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

Schneider BJ, Naidoo J, Santomaso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. *J Clin Oncol*. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440



Glossary

1L, first line
AE, adverse event
ALT, alanine aminotransferase
CR, complete response
dMMR, mismatch repair deficient
DOR, duration of response
Dosta, dostarlimab
EOC, epithelial ovarian cancer
FR, folate receptor
G, grade
GBS, Guillain-Barré syndrome
HRp, homologous recombination proficient
IO, immunotherapy
irAE, immune-related adverse event
MSI-H, microsatellite instability high
NA, not applicable
NR, not reached
OC, ovarian cancer
ORR, objective response rate
OS, overall survival
Pembro, pembrolizumab
PFS, progression-free survival
T1DM, type 1 diabetes mellitus
TMB-H, tumor mutational burden high
TRAE, treatment-related adverse event
w/, with
yo, year old